{"id":"thalidomide-100mg","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Neuropathy"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Constipation"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL426123","moleculeType":"Small molecule","molecularWeight":"258.23"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Thalidomide also has anti-angiogenic properties, inhibiting the formation of new blood vessels that supply tumors. Additionally, it can induce apoptosis in cancer cells and modulate the immune response to promote anti-tumor activity.","oneSentence":"Thalidomide acts as an immunomodulatory agent, inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and other pro-inflammatory cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:11.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma"},{"name":"Erythema nodosum leprosum"}]},"trialDetails":[{"nctId":"NCT06617182","phase":"PHASE2","title":"Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury.","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2024-09-30","conditions":"Radiation Enteritis","enrollment":150},{"nctId":"NCT06031012","phase":"PHASE3","title":"Glutamine Combined With Thalidomide in Preventing Radiation-induced Oral Mucositis","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2023-09-15","conditions":"Mucositis Oral","enrollment":138},{"nctId":"NCT02858804","phase":"PHASE4","title":"EDOCH Alternating With DHAP for New Diagnosed Younger MCL","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-01","conditions":"Mantle Cell Lymphoma","enrollment":55},{"nctId":"NCT06530576","phase":"PHASE2","title":"Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-08-10","conditions":"T-LGL Leukemia, NK-LGL Leukemia","enrollment":48},{"nctId":"NCT07204041","phase":"PHASE2","title":"Efficacy and Safety of XTD Regimen (Selinexor, Thalidomide and Dexamethasone) in Adult Patients With Relapsed/Refractory LCH","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":40},{"nctId":"NCT07187193","phase":"PHASE2","title":"Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-04-12","conditions":"Langerhans Cell Histiocytosis","enrollment":50},{"nctId":"NCT06490601","phase":"PHASE2","title":"Long Term Beta Thalassemia Treatment: Findings From The Extension Period","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2022-04-01","conditions":"Fetal Hemoglobin, Beta-Thalassemia, Hemoglobinopathies","enrollment":30},{"nctId":"NCT06231680","phase":"PHASE2","title":"Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2024-01-19","conditions":"Lung Cancer, Nonsmall Cell, Esophageal Carcinoma","enrollment":132},{"nctId":"NCT02891811","phase":"PHASE2","title":"Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2017-03-10","conditions":"Multiple Myeloma","enrollment":124},{"nctId":"NCT06239389","phase":"PHASE2","title":"Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study.","status":"COMPLETED","sponsor":"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan","startDate":"2021-09-01","conditions":"Beta-Thalassemia","enrollment":24},{"nctId":"NCT06276933","phase":"PHASE4","title":"A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"Tongji University","startDate":"2024-02-22","conditions":"Lung Cancer, Camrelizumab","enrollment":104},{"nctId":"NCT00777998","phase":"PHASE2","title":"Auto-Allo Tandem Stem Cell Transplantation for Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-10-14","conditions":"Multiple Myeloma","enrollment":221},{"nctId":"NCT02707484","phase":"PHASE3","title":"the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2016-04","conditions":"Gastrointestinal Vascular Malformation","enrollment":150},{"nctId":"NCT04941937","phase":"PHASE2","title":"Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM","status":"UNKNOWN","sponsor":"Juan Du","startDate":"2022-01-27","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT05525234","phase":"PHASE4","title":"A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2022-09-15","conditions":"Haemodialysis, Uremic Pruritus, Thalidomide","enrollment":40},{"nctId":"NCT05266820","phase":"PHASE2","title":"Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2021-10-01","conditions":"Metastatic Colorectal Cancer","enrollment":120},{"nctId":"NCT05198856","phase":"PHASE1, PHASE2","title":"Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-10","conditions":"Gastric Cancer Metastatic to Liver","enrollment":106},{"nctId":"NCT03122431","phase":"PHASE4","title":"Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2017-06-05","conditions":"Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus","enrollment":93},{"nctId":"NCT04120519","phase":"PHASE2","title":"Thalidomide, Cyclophosphamide and Dexamethasone for Recurrent/Refractory Adult Langerhans Cell Histiocytosis","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-10-10","conditions":"Langerhans Cell Histiocytosis","enrollment":20},{"nctId":"NCT00538733","phase":"PHASE2","title":"Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-10","conditions":"Multiple Myeloma","enrollment":26},{"nctId":"NCT04891744","phase":"PHASE1, PHASE2","title":"Selinexor in Combination With Thalidomide and Dexamethasone in RRMM","status":"UNKNOWN","sponsor":"Li Zheng","startDate":"2021-07-06","conditions":"Multiple Myeloma","enrollment":48},{"nctId":"NCT02085655","phase":"PHASE3","title":"PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma","status":"UNKNOWN","sponsor":"Huiqiang Huang","startDate":"2013-04-25","conditions":"Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type","enrollment":264},{"nctId":"NCT04612582","phase":"PHASE4","title":"Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis","status":"UNKNOWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2020-01-01","conditions":"Immunoglobulin Light-Chain Amyloidosis","enrollment":70},{"nctId":"NCT00274820","phase":"PHASE2","title":"Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2005-10","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes","enrollment":15},{"nctId":"NCT04453345","phase":"PHASE2, PHASE3","title":"TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL","status":"UNKNOWN","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2013-05-20","conditions":"T-LGL Leukemia, Clpd-Nk","enrollment":42},{"nctId":"NCT03043105","phase":"PHASE2","title":"TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-01-01","conditions":"Multicentric Castleman Disease","enrollment":25},{"nctId":"NCT02733380","phase":"PHASE2","title":"Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2016-05","conditions":"Diffuse Large B-cell Lymphoma","enrollment":20},{"nctId":"NCT04273581","phase":"PHASE2","title":"The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-02-18","conditions":"COVID-19 Thalidomide","enrollment":40},{"nctId":"NCT04273529","phase":"PHASE2","title":"The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2020-02-20","conditions":"COVID-19 Thalidomide","enrollment":100},{"nctId":"NCT02410694","phase":"PHASE2","title":"Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2015-04","conditions":"Multiple Myeloma","enrollment":90},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT00452569","phase":"PHASE3","title":"Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2006-02-01","conditions":"Multiple Myeloma","enrollment":499},{"nctId":"NCT00657488","phase":"PHASE2, PHASE3","title":"Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2001-12-01","conditions":"Multiple Myeloma","enrollment":400},{"nctId":"NCT03062800","phase":"PHASE2","title":"Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2016-12","conditions":"Advanced Nsclc","enrollment":232},{"nctId":"NCT02879526","phase":"PHASE2","title":"Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2016-08","conditions":"Relapse/Refratory Peripheral T Cell Lymphoma","enrollment":45},{"nctId":"NCT00151281","phase":"PHASE2","title":"Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2004-11","conditions":"Non-Hodgkin's Lymphoma","enrollment":25},{"nctId":"NCT03562169","phase":"PHASE3","title":"The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII (ACCoRd)","status":"RECRUITING","sponsor":"University of Leeds","startDate":"2017-03-20","conditions":"Multiple Myeloma","enrollment":406},{"nctId":"NCT03143036","phase":"PHASE2","title":"Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2018-05-01","conditions":"Relapse and / or Refractory Myeloma","enrollment":100},{"nctId":"NCT00538824","phase":"PHASE2","title":"Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2007-12","conditions":"Multiple Myeloma","enrollment":5},{"nctId":"NCT00529633","phase":"PHASE3","title":"The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients","status":"TERMINATED","sponsor":"George A. Kaysen, M.D.","startDate":"2007-09","conditions":"Hypoalbuminemia","enrollment":16},{"nctId":"NCT03140943","phase":"PHASE2","title":"Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2017-09-13","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":100},{"nctId":"NCT00081939","phase":"PHASE2","title":"UARK 2003-33, Total Therapy III","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2004-01","conditions":"Multiple Myeloma","enrollment":303},{"nctId":"NCT03273452","phase":"PHASE2","title":"Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2017-03-01","conditions":"Angioimmunoblastic T-cell Lymphoma","enrollment":30},{"nctId":"NCT00670631","phase":"PHASE2","title":"Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment","status":"COMPLETED","sponsor":"Guido Tricot","startDate":"2008-02","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT03204032","phase":"PHASE2","title":"A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-10","conditions":"Extrapancreatic Neuroendocrine Tumor","enrollment":60},{"nctId":"NCT03204019","phase":"PHASE2","title":"A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2016-10","conditions":"Pancreatic Neuroendocrine Tumor","enrollment":60},{"nctId":"NCT02981199","phase":"NA","title":"Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients","status":"UNKNOWN","sponsor":"Chen Wenming","startDate":"2016-01","conditions":"Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse","enrollment":80},{"nctId":"NCT02956538","phase":"EARLY_PHASE1","title":"Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2016-10","conditions":"Crohn Disease","enrollment":72},{"nctId":"NCT02778893","phase":"PHASE4","title":"Conmana Combined With Thalidomide to Treat NSCLC","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2016-03","conditions":"NSCLC","enrollment":67},{"nctId":"NCT00892346","phase":"PHASE3","title":"Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma","status":"SUSPENDED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2009-05","conditions":"Multiple Myeloma","enrollment":80},{"nctId":"NCT00971126","phase":"PHASE1, PHASE2","title":"Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC)","status":"TERMINATED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2009-07","conditions":"Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT02754960","phase":"PHASE2","title":"Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding","status":"WITHDRAWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2010-03","conditions":"Gastrointestinal Hemorrhage, Vascular Malformation","enrollment":""},{"nctId":"NCT02501291","phase":"PHASE2","title":"Thalidomide in Treating Crohn's Disease","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2013-01","conditions":"Crohn's Disease","enrollment":47},{"nctId":"NCT02649101","phase":"PHASE2","title":"Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2015-10","conditions":"Metastatic Breast Cancer","enrollment":60},{"nctId":"NCT00083551","phase":"PHASE3","title":"UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"1998-08","conditions":"Multiple Myeloma","enrollment":668},{"nctId":"NCT02201043","phase":"PHASE2","title":"Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Shanghai Pharmaceuticals Holding Co., Ltd","startDate":"2013-02","conditions":"Ankylosing Spondylitis","enrollment":197},{"nctId":"NCT02145715","phase":"PHASE1, PHASE2","title":"Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma","status":"UNKNOWN","sponsor":"Prof Jamie Cavenagh","startDate":"2013-01","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT02467647","phase":"PHASE1","title":"The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2015-01","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT02387086","phase":"PHASE2, PHASE3","title":"Gefitinib Combined With Thalidomide to Treat NSCLC","status":"UNKNOWN","sponsor":"Bai Jun","startDate":"2015-05","conditions":"NSCLC","enrollment":380},{"nctId":"NCT02240771","phase":"PHASE2, PHASE3","title":"Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2006-01","conditions":"Hepatocellular Carcinoma","enrollment":124},{"nctId":"NCT01924624","phase":"NA","title":"Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2013-07","conditions":"Hepatocellular Carcinoma, Recurrence","enrollment":140},{"nctId":"NCT00522405","phase":"PHASE2, PHASE3","title":"Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2007-10","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT01328236","phase":"PHASE2","title":"Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia","status":"UNKNOWN","sponsor":"Clinical Service, China","startDate":"2010-09","conditions":"Plasma Cell Leukemia, Multiple Myeloma","enrollment":20},{"nctId":"NCT00165451","phase":"PHASE2","title":"A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-06","conditions":"Neoplasms","enrollment":20},{"nctId":"NCT00083460","phase":"PHASE1","title":"Study of Combination PS-341 and Thalidomide in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2001-12","conditions":"Multiple Myeloma","enrollment":86},{"nctId":"NCT00644306","phase":"PHASE3","title":"Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma","status":"TERMINATED","sponsor":"Central Hospital, Nancy, France","startDate":"2002-04","conditions":"Newly Diagnosed, Multiple Myeloma","enrollment":232},{"nctId":"NCT00140452","phase":"PHASE2","title":"Phase II Study Using Thalidomide for the Treatment of ALS","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2005-02","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["thalido","Thalidomide","Thalomid","Fan Ying Ting","Group 1"],"phase":"phase_3","status":"active","brandName":"Thalidomide (100mg)","genericName":"Thalidomide (100mg)","companyName":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","companyId":"cancer-institute-and-hospital-chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Thalidomide acts as an immunomodulatory agent, inhibiting the release of tumor necrosis factor-alpha (TNF-alpha) and other pro-inflammatory cytokines. Used for Multiple myeloma, Erythema nodosum leprosum.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}